The TRPV6 inhibitor SOR-C13 is already in Phase I clinical trials in patients with advanced solid cancers and is approved as an orphan drug for pancreatic and ovarian cancers [73]. This evidence concerns the gene TRPV6 and ovarian carcinoma.